Amneal Pharmaceuticals received FDA approval for its romidepsin injection solution, a ready-to-use cancer treatment for cutaneous T-cell lymphoma. The product is eligible for Competitive Generic Therapy designation, giving Amneal 180 days of market exclusivity. This approval revives a previously withdrawn treatment and supports Amneal's focus on expanding its injectables business. The drug's U.S. sales reached about $78 million annually before withdrawal, indicating strong market potential.
GNI Group has agreed to acquire 100% of Ayumi Pharmaceutical Holdings from shareholders led by Blackstone for about ¥44.8 billion. This acquisition significantly expands GNI's commercial footprint in Japan, especially in pain management and rheumatol...
Gen Digital Inc. is showing stable free cash flow supported by a slowly growing subscription base, making it attractive in today's volatile market influenced by consumer uncertainty and AI developments. The stock currently yields about 10% in free ca...
Tyson Foods reported strong Q2 results, surpassing sales and earnings expectations, and raised its free cash flow guidance for fiscal year 2026 to between $1.2 and $1.8 billion. The company also reduced its total debt by $747 million, strengthening i...
The Fidelity High Dividend ETF (FDVV) stands out with an attractive 3.00% estimated dividend yield and a forward price-to-earnings ratio of 16.70, trading at a discount compared to S&P 500 Index ETFs. Its unique combination of quality, growth, and in...
About $315 million in leveraged crypto positions, mostly long trades, were liquidated in the past 24 hours, signaling a market reset. The liquidations, concentrated on Binance and focused on Bitcoin and Ethereum, cleared crowded bullish bets and ease...
